Cipla Share Price: USFDA ka bada approval, ab GSK ka **$1.5 Billion** market Cipla ke target par!

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAnanya Iyer|Published at:
Cipla Share Price: USFDA ka bada approval, ab GSK ka **$1.5 Billion** market Cipla ke target par!
Overview

USFDA ne finally Cipla ko unke generic albuterol sulfate inhalation aerosol ke liye final approval de diya hai. Yeh GlaxoSmithKline (GSK) ke Ventolin HFA ka pehla AB-rated equivalent hai, jo **$1.5 Billion** ke U.S. market mein entry karne wala hai.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

USFDA ki Manzoori: Cipla ke liye game changer?

USFDA ne Cipla ke generic albuterol sulfate inhalation aerosol (90 mcg per actuation) ko green signal de diya hai. Yeh approval Cipla ke liye respiratory segment mein ek bada move hai, jahan woh bade players jaise GSK ko takkar dene ki poori koshish karegi.

Kya hai iska matlab?

AB-rated approval ka matlab hai ki yeh generic product branded Ventolin HFA ka direct substitute ban sakta hai. America mein albuterol market lagbhag $1.5 Billion ka hai (IQVIA data ke mutabik), aur Cipla ki yeh entry market mein competition ko aur badha degi. Is news ke baad Cipla ke shares mein 4% se zyada ka jump bhi dekha gaya.

GSK ka market share khatre mein?

GSK ka Ventolin HFA jabki patent expiry ke baad bhi market mein dominant tha (2022 mein estimated 55% share), generics ka hissa sirf 20% tha. Waise toh Cipla ka already U.S. albuterol market mein 22% share hai (October 2025 tak), lekin is AB-rated approval se company ko aur bhi bada share grab karne ka mauka milega. Experts ke hisaab se, Cipla ki valuation (P/E ratio lagbhag 21-22) industry average (32+) ke muqable attractive hai, jabki GSK ka P/E 15-16 hai.

Aage ki chunautiyan aur analysts ka kehna

Analysts ke views mix hain, kuch 'Neutral' bol rahe hain toh kuch 'Buy' rating de rahe hain, aur 15-19% tak upside potential dekh rahe hain. Lekin market mein stiff competition aur price cuts ek badi challenge hai. Pehle bhi USFDA ke observations par Cipla ke stocks girawe hain, aur GSK ne bhi Ventolin recalls face kiye hain. Teva jaise competitors bhi active hain.

Cipla ka future plan

Cipla ka plan hai ki is generic albuterol inhaler ko jaldi se jaldi launch kar ke market share pakka karein. Saath hi, company fiscal year 2026-27 tak kai aur complex generics products launch karne wali hai, jisse respiratory segment mein unki position aur mazboot ho sake.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.